In-vivo Prime Editing Platform Market Report 2025

The in-vivo prime editing platform market size has grown exponentially in recent years. It will grow from $0.97 billion in 2024 to $1.26 billion in 2025 at a compound annual growth rate (CAGR) of 29.5%. The growth during the historic period is driven by increasing clinical applications, rising healthcare expenditures, growing prevalence of genetic diseases, expanding adoption of prime editing technologies, and higher investments in genomic research.

The in-vivo prime editing platform market size is expected to see exponential growth in the next few years. It will grow to $3.5 billion in 2029 at a compound annual growth rate (CAGR) of 29.2%. The projected growth in the forecast period is supported by rising demand for personalized medicine, increasing prevalence of hereditary diseases and cancer, greater funding from public and private sectors, higher patient awareness, and broader adoption of gene editing therapies. Key trends in this period include advancements in delivery systems, innovations in guide RNA design, integration of artificial intelligence and machine learning, development of lipid nanoparticle (LNP) platforms, and growth in strategic collaborations and partnerships.

The growing demand for precise and efficient genome-editing solutions is expected to drive the expansion of the in-vivo prime editing platform market. Genome editing involves making accurate, targeted changes to DNA - the molecule that carries genetic information - while minimizing unintended edits and potential side effects. This demand is largely driven by the increasing need for targeted therapies that reduce errors and provide lasting clinical benefits. In-vivo prime editing platforms address this need by enabling highly accurate, targeted DNA corrections within living tissues, with minimal off-target effects and the potential for long-term therapeutic benefits. For instance, the World Economic Forum reported that over 2,000 gene therapies were in development worldwide, double the number from just three years ago. As a result, the rising demand for precise and efficient genome-editing solutions is contributing to the growth of the in-vivo prime editing platform market.

Companies in the in-vivo prime editing platform market are focusing on innovations in delivery systems to improve the targeting and accessibility of in-vivo therapies. Advanced delivery methods, such as lipid nanoparticles, viral vectors, and engineered extracellular vesicles, are crucial for encapsulating prime editing components such as Cas9 nickase, reverse transcriptase, and pegRNAs. These carriers protect the editing tools from degradation, facilitate efficient delivery into target cells, and improve tissue specificity. For example, in September 2023, Moderna, a US-based biotechnology company, demonstrated that optimized lipid nanoparticle formulations could deliver prime editing machinery to liver and muscle tissues in animal models with high precision. This allowed targeted genome modifications while minimizing off-target effects, showcasing how innovations in delivery systems are enhancing the precision and therapeutic potential of in-vivo prime editing therapies.

In July 2025, Eli Lilly and Company, a US-based pharmaceutical firm, acquired Verve Therapeutics, Inc. for an undisclosed sum. This acquisition aims to revolutionize the treatment of cardiovascular disease by developing one-time genetic therapies that provide lifelong cardiovascular risk reduction. Verve Therapeutics is a clinical-stage biotechnology company focused on using gene-editing technologies to develop genetic medicines for cardiovascular conditions.

Major players in the in-vivo prime editing platform market are AstraZeneca PLC, Danaher Corporation, Regeneron Pharmaceuticals Inc., Moderna Inc., Integrated DNA Technologies Inc., Beam Therapeutics Inc., CRISPR Therapeutics AG, Maravai LifeSciences Holdings Inc., Sangamo Therapeutics Inc., Editas Medicine Inc., Precision BioSciences Inc., Metagenomi Inc., Tessera Therapeutics Inc., Mammoth Biosciences Inc., Arbor Biotechnologies Inc., Intellia Therapeutics Inc. (NTLA), Caribou Biosciences Inc., Scribe Therapeutics Inc., EGENESIS INC., Prime Medicine Inc., Cellectis S.A.

North America was the largest region in the in-vivo prime editing platform market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in in-vivo prime editing platform report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the in-vivo prime editing platform market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The fast surge in U.S. tariffs and the trade tensions that followed in spring 2025 are heavily affecting the medical equipment sector, particularly for imported imaging machine components, surgical-grade stainless steel, and plastic disposables. Hospitals and clinics resist price hikes, pressuring manufacturers’ margins. Regulatory hurdles compound the problem, as tariff-related supplier changes often require re-certification of devices, delaying time-to-market. Companies are mitigating risks by dual-sourcing critical parts, expanding domestic production of commoditized items, and accelerating R&D in cost-efficient materials.

The in-vivo prime editing platform is an advanced genome editing technology that allows precise, targeted DNA modifications directly within living organisms. It integrates a catalytically impaired CRISPR-Cas enzyme with a reverse transcriptase and employs a prime editing guide RNA (pegRNA) to introduce specific base changes, insertions, or deletions without causing double-strand breaks. This technique enables accurate correction of genetic mutations in tissues or organs, holding significant promise for therapeutic applications, particularly for inherited genetic disorders.

The primary product categories in the in-vivo prime editing platform include prime editing enzymes, guide RNAs (gRNAs), delivery systems, and related products. Prime editing enzymes are engineered proteins formed by fusing CRISPR-associated protein 9 nickase (Cas9 H840A) with reverse transcriptase (RT), typically derived from Moloney murine leukemia virus reverse transcriptase (M-MLV RT). In this system, the Cas9 nickase introduces a single-strand break in DNA, while the reverse transcriptase uses an RNA template to directly implement the intended modification. This allows precise search-and-replace genome editing without double-strand breaks, enhancing both safety and efficiency. Demand for prime editing enzymes is increasing alongside the advancement of clinical gene editing.

The in-vivo prime editing platform market research report is one of a series of new reports that provides in-vivo prime editing platform market statistics, including in-vivo prime editing platform industry global market size, regional shares, competitors with the gene circuit therapeutics market share, in-vivo prime editing platform market segments, market trends, and opportunities, and any further data you may need to thrive in the in-vivo prime editing platform industry. This in-vivo prime editing platform market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The in-vivo prime editing platform market consists of revenues earned by entities by providing services such as gene sequencing, genetic analysis, CRISPR -based editing, therapeutic development, preclinical testing. The market value includes the value of related goods sold by the service provider or included within the service offering. The in-vivo prime editing platform market also includes sales of gene editing kits, reagents, enzymes, plasmids, delivery vectors. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.